- Zebrafish lines
- Zebrafish Facilities
- Anti-angiogenesis assays
- Acute Toxicity Assays
- Developmental Toxicity Assays
- Drug screening and discovery
- Producing genetically modified fish
- Using disease models and high throughput phenotyping screening
Are new anticancer therapies developed by your new research based on anti-angiogenesis? Let us help you to assess this effect in a short time.
Introduction
Royan Zebrafish Core Facility is a research laboratory offering the newest and most up-to-date research that can accompany your studies.
Zebrafish (Danio rerio) is a powerful model system in cancer research. De novo vessel formation, called angiogenesis seems essential for the progression and spreading of tumors. Today, anticancer therapies based on anti-angiogenesis are being developed.
The transgenic zebrafish lines, fli:EGFP and flk:GFP are present in the Royan zebrafish core facility which are used for these types of investigations. Vessels are seen by green color under the fluorescent stereomicroscope, which makes it possible to follow up the fluorescent angiogenesis and antiangiogenetic anti-cancer drugs effects.
Method Description
Zebrafish embryos are exposed to at least 3 different doses of compounds in a 24-well microplate containing 1500 ml E3 medium, after determining of appropriate concentration of the drug. Anti-angiogenesis assays are done in 3 repeats, and replications
Readouts
To evaluate outgrowth, at 30-hpf, larvae chorions are removed and taken picture under a fluorescent stereomicroscope. Angiogenesis is scored that takes into account the approximate number of outgrowing vessels (100, 75, 50, 25, or 0%). Scoring results are analyzed with GraphPad prism and usually one-way ANOVA is used. The results will be reported by chart and pictures.
Figures
Figure 1: The GraphPad prism result are shown by charts
Figure 2: The zebrafish larvae, representative image of green florescence to show angiogenesis activity a. normal angiogenesis b. absence of ISVs